Latest Proprietary Technology News

Papyrus Australia has secured a pivotal contract with UniSA to establish a Rapid Prototyping and R&D facility, advancing its sustainable packaging technology and commercial production plans.

Cardiex Digital Vascular Biomarkers announces a A$6.5 million equity raise to fund inventory, marketing, product development, and debt repayment, aiming to solidify its position in the expanding cardiovascular health market.

RareX Limited has partnered with Gega Elements to develop Australia’s inaugural integrated gallium supply chain, aiming to reduce reliance on Chinese supply and boost national critical mineral resilience.

Smartpay has reported an 8.5% rise in consolidated revenue for FY2025, driven by growth in Australia and a bold entry into New Zealand’s acquiring market. However, investments in technology and market expansion have weighed on EBITDA.

Zelira Therapeutics has published full results from a Phase I study showing its cannabinoid-based therapy ZLT-L-007 significantly outperforms Lyrica® in managing diabetic neuropathy pain and related symptoms.

Bell Financial Group delivered strong financial results for 2024, driven by growth in technology and product services, but early 2025 shows challenges from market volatility impacting core broking revenues.

Plenti Group Limited reported a stellar FY25 with a 126% surge in Cash NPAT to $13.8 million, driven by robust loan portfolio growth and operational efficiency. The fintech lender is targeting a $3 billion loan book by March 2026, leveraging technology and strategic partnerships.

Plenti Group Limited reported a robust FY25 with a 126% jump in Cash NPAT to $13.8 million and a 19% increase in its loan portfolio to $2.5 billion, driven by technology enhancements and strategic partnerships.

Plenti Group Limited has reported a remarkable turnaround with a $24.8 million profit for the year ended March 2025, reversing a loss from the previous year. The fintech lender also announced its upcoming Annual General Meeting and director nomination deadlines.

Worley Limited has reaffirmed its FY25 financial outlook, targeting low double-digit EBITA growth and margins between 8-8.5%, supported by a robust $9.4 billion bookings pipeline and a strategic operational reorganisation.

Australian Bond Exchange Holdings has completed a $683,180 private placement, issuing over 17 million shares to strengthen its financial position and support expansion and cost-cutting initiatives.

Mesoblast has been granted a seven-year orphan-drug exclusivity by the FDA for its cell therapy Ryoncil, reinforcing its market position in treating steroid-refractory acute graft versus host disease in children.